ABBV vs. BMY: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABBV and BMY, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ABBV dominates in value with a market cap of 321.13 billion USD, eclipsing BMY’s 95.18 billion USD by roughly 3.37×.
With betas of 0.55 for ABBV and 0.40 for BMY, both show similar volatility profiles relative to the overall market.
| Symbol | ABBV | BMY |
|---|---|---|
| Company Name | AbbVie Inc. | Bristol-Myers Squibb Company |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| CEO | Mr. Robert A. Michael CPA | Dr. Christopher S. Boerner Ph.D. |
| Price | 181.8 USD | 46.77 USD |
| Market Cap | 321.13 billion USD | 95.18 billion USD |
| Beta | 0.55 | 0.40 |
| Exchange | NYSE | NYSE |
| IPO Date | January 2, 2013 | June 1, 1972 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ABBV and BMY over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ABBV and BMY based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- BMY shows a negative forward PEG of -3.01, signaling expected earnings contraction, while ABBV at 7.16 maintains analysts’ projections for stable or improved profits.
| Symbol | ABBV | BMY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 76.62 | 17.53 |
| Forward PEG Ratio (TTM) | 7.16 | -3.01 |
| Price-to-Sales Ratio (P/S, TTM) | 5.60 | 2.00 |
| Price-to-Book Ratio (P/B, TTM) | 226.35 | 5.46 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 20.87 | 7.27 |
| EV-to-EBITDA (TTM) | 23.58 | 8.38 |
| EV-to-Sales (TTM) | 6.73 | 2.85 |
| EV-to-Free Cash Flow (TTM) | 25.08 | 10.36 |
Dividend Comparison
Both ABBV and BMY offer similar dividend yields (3.51% vs. 5.22%), indicating comparable approaches to balancing income and growth.
| Symbol | ABBV | BMY |
|---|---|---|
| Dividend Yield (TTM) | 3.51% | 5.22% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ABBV and BMY, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ABBV’s current ratio of 0.76 signals a possible liquidity squeeze, while BMY at 1.28 comfortably covers its short-term obligations.
- ABBV’s quick ratio of 0.64 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas BMY at 1.17 maintains a comfortable buffer of liquid assets.
- ABBV is heavily leveraged (debt-to-equity ratio 49.22), which can boost returns but raises risk if borrowing costs climb, while BMY at 2.95 keeps leverage at a more moderate level.
| Symbol | ABBV | BMY |
|---|---|---|
| Current Ratio (TTM) | 0.76 | 1.28 |
| Quick Ratio (TTM) | 0.64 | 1.17 |
| Debt-to-Equity Ratio (TTM) | 49.22 | 2.95 |
| Debt-to-Assets Ratio (TTM) | 0.51 | 0.55 |
| Interest Coverage Ratio (TTM) | 6.14 | 4.36 |